AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 11 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Medical collaborators in Japan and Sweden have completed a phase I trial of peptide-pulsed dendritic cells in gastric cancer patients.
Scientists have identified the tumor-associated antigen HER-2/neu in some gastric cancers. Previous studies have shown dendritic cells made to overexpress the oncogene HER-2/neu act as cancer antigens in tumor vaccines. Medical researchers are currently evaluating whether or not such vaccines would be effective for treating gastric cancer.
Koji Kono and colleagues, Yamanashi Medical University, Japan, collaborated with medical investigators at Karolinska Hospital in Stockholm, Sweden, to conduct the clinical trial of nine gastric cancer patients.
According to Kono and coauthors, each of the patients had tumors that overexpressed HER-2/neu. In addition, each of the patients was positive for HLA-A2 cytotoxic specific lymphocytes (CTLs), signaling their ability to process tumor antigens.
Researchers administered four doses of the HER-2/neu-pulsed cells to each of the patients.
"There were no serious adverse effects noted in the immunized patients," said Kono and coauthors.
A survey of the patient's cells before and after immunization showed that before immunization, none had developed antigen-specific recognition of the HER-2/neu peptide. After immunization, six of the nine patients exhibited antigen-specific response (Dendritic cells pulsed with ...
Source: HighBeam Research, Tumor vaccine raises antigen-specific response in gastric cancer...